1 / 5

The DELIVER Trial

The DELIVER Trial. A Multi-Center, Randomized Study of the Paclitaxel-Eluting Stent in the Treatment of Patients with De Novo Coronary Artery Lesions Presented at ACC 2003 Late Breaking Clinical Trials. DELIVER: Study Design.

sook
Télécharger la présentation

The DELIVER Trial

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The DELIVER Trial A Multi-Center, Randomized Study of the Paclitaxel-Eluting Stent in the Treatment of Patients with De Novo Coronary Artery Lesions Presented at ACC 2003 Late Breaking Clinical Trials

  2. DELIVER: Study Design 1,043 patients with de novo lesions in native coronary arteries <25 mm in length and 2.5 to 4.0 mm in diameter, randomized to: MULTI-LINK RX PENTA™ stent (n=519) RX ACHIEVE™Stent Coated with Paclitaxel (n=522) + + ASA for 1 year Clopidogrel for 3 months ASA for 1 year Clopidogrel for 3 months 8 Month Angiographic study Target Vessel Failure (TVF) (Death / MI / TLR) ACC 2003 Late Breaking Trials

  3. DELIVER: 8 Month In-stent Angiographic Results Late Loss Binary Restenosis p = 0.003 p = 0.149 (mm) (%) Bare Stent Paclitaxel Coated Paclitaxel Coated Bare Stent ACC 2003 Late Breaking Trials

  4. DELIVER: 9 Month Clinical Event Results Death TVF* MI p=0.079 p=NS p=NS Paclitaxel Coated Paclitaxel Coated Paclitaxel Coated Bare Stent Bare Stent Bare Stent * TVF = Death/MI/TLR

  5. DELIVER: Conclusions • Treatment of de novo lesions with a paclitaxel-eluting stent was not associated with a reduction in target vessel failure at 9 months binary restenosis • Late loss on 8 month angiographic follow-up was reduced in paclitaxel-eluting stent arm but no difference in binary restenosis • TAXUS II trial showed a reduction in death, MI or TVR with a paclitaxel-coated stent; however, TAXUS II used polymeric paclitaxel-eluting stent but DELIVER used non-polymeric ACC 2003 Late Breaking Trials

More Related